Page 12 - reflections_dyslipidaemia_newsletter5_2023
P. 12
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #6 2023
ADDITIONAL ARTICLES OF INTEREST Dyslipidaemia
GUIDELINES/STATEMENTS
1. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Marx N, et al. Eur
Heart J. 2023 Oct 14;44(39):4043-4140.
2. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients with Chronic Coronary Disease:
A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice
Guidelines. Writing Committee Members. Am Coll Cardiol. 2023 Aug 29;82(9):833-955.
PATHOPHYSIOLOGY
3. Non-HDL cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. Raja V et al.
Atherosclerosis. 2023 Oct:383:117312.
4. Relating lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: A comparison of
three tests. Szarek M, et al. Circulation. 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066398. Online ahead of print.
5. Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The multi-ethnic study of
atherosclerosis. Bhatia HS, et al. Atherosclerosis. 2023 Sep:381:117217.
EPIDEMIOLOGY
6. Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events: A
population-based cohort study. Cho SMJ, et al. Eur Heart J. 2023 Sep 21;44(36):3456-3465.
7. Cardiometabolic risk management: Insights from a European Society of Cardiology Cardiovascular Round Table.
Cosentino F, et al. Eur Heart J. 2023 Oct 14;44(39):4141-4156.
8. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: A UK Biobank
study. Björnson E, et al. Eur Heart J. 2023 Oct 14;44(39):4186-4195.
9. Impact of conducting a genetic study on the management of familial hypercholesterolemia. Marco-Benedí V, et al. J
Clin Lipidol. 2023 Sep 9:S1933-2874(23)00261-1.
TREATMENT
10. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.
Cordero A, et al. J Clin Lipidol. 2023 Sep-Oct;17(5):602-611.
11. LDL-C reduction with lipid-lowering therapy for primary prevention of major vascular events among older
individuals. Andersson NW, et al. J Am Coll Cardiol. 2023 Oct 3;82(14):1381-1391.
12. Intensive statin therapy versus upfront combination therapy of statin and ezetimibe in patients with acute coronary
syndrome: A propensity score matching analysis based on the PL-ACS data. Lewek J, et al. J Am Heart Assoc. 2023
Sep 19;12(18):e030414.
13. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60
randomized trials, overall and by dose, ethnicity, and drug type. Bechmann LE, et al. Atherosclerosis. 2023 Aug
9:117236.
14. Low adherence to the Mediterranean diet is associated with increased prevalence and number of atherosclerotic
plaques in the ILERVAS cohort. Rojo-López MI, et al. Atherosclerosis. 2023 Sep:380:117191.
15. Atorvastatin for anthracycline-associated cardiac dysfunction: The STOP-CA randomized clinical trial. Neilan TG, et
al. JAMA. 2023 Aug 8;330(6):528-536.
TABLE OF CONTENTS
